Pioneering treatments for rare orphan conditions and unmet needs in women's health.

HAVAH Therapeutics is a women’s health speciality biopharmaceutical company.

We are focused on developing innovative, proprietary hormonal therapies that aim to help millions of women across the world lead longer, better lives.

A leading biopharma focused on improving women's health.

About our business.

HAVAH Therapeutics lead drug candidate HAVAHT+Ai™ is currently undergoing late-stage clinical trials into targeted areas of unmet needs and disease states with orphan designation in women's health.

We are dedicated to delivering value to our stakeholders through efficient execution and a commitment to building a sustainable enterprise. 

Our team.

We bring together a world class team passionate about helping women live lives free from the suffering caused by rare and debilitating orphan conditions and unmet needs in women's health.

Dr Stephen Birrell, MD PhD
CMO & Founder

Founder and inventor, 30-year breast cancer specialist/surgeon and renowned medical innovator, clinical oncologist, widely published molecular oncologist in leading journals incl. Nature, founder/ pioneer of three leading (Australian) multi-disciplinary breast centres in both the public and private sectors.

Mr Nicholas J. Birrell
Managing Director

Founding CEO of HAVAH, experienced start-up CEO, co-founder of Wellend Health leading Australian breast cancer clinics, founder/CEO of LOKE Group (Exited) Asia-Pacific mobile technology developer delivering solutions to a number of Fortune 500 clients.

Ms Kathy Harrison, MSc, FIPTA, GAICD

More than 25 years in biotechnology including 9 years in patent attorney practice. Leadership roles in biotech companies have included CEO of ASX listed Dimerix Ltd and current Director of Disruptive Nutrition Pty Ltd. Kathy has extensive experience in intellectual property strategy, commercial drug development strategy and achieving drug development milestones. Kathy's qualifications in science, intellectual property law and governance provide the depth of skill to lead HAVAH through its next stage of growth.

Mr Ronald A. Martell

Experienced biotechnology and pharma industry executive with 25 years' experience at a senior management level,  most recently at Sevion Therapeutics, NeurogesX and Poniard Pharmaceuticals. Ex-Group Manager, Oncology at Genetech, Ex-SVP of Commercial Operations at ImClone Systems.


Nyroca House, 10-20 New Street, North Adelaide, South Australia 5006, Australia

Copyright 2020 HAVAH Therapeutics